These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10101208)

  • 21. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
    Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
    Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Contemporary possibilities of prognosis in myelodysplastic syndromes].
    Goździk J; Lewandowski K; Hansz J
    Acta Haematol Pol; 1995; 26(2):129-38. PubMed ID: 7653217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution.
    Balduini CL; Guarnone R; Pecci A; Centenara E; Invernizzi R; Ascari E
    Haematologica; 1999 Jan; 84(1):12-6. PubMed ID: 10091387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic classification in myelodysplastic syndromes.
    Sanz GF; Morel P
    Pathol Biol (Paris); 1997 Oct; 45(8):617-26. PubMed ID: 9569927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS).
    Fenaux P
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
    Hui CH; Horvath N; Lewis I; To LB; Szabo F
    Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
    Singh ZN; Huo D; Anastasi J; Smith SM; Karrison T; Le Beau MM; Larson RA; Vardiman JW
    Am J Clin Pathol; 2007 Feb; 127(2):197-205. PubMed ID: 17210514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in supportive care of myelodysplastic syndromes.
    Gordon MS
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Bowen DT
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.
    Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstöcker M; Rüter B; Sperr WR; Stauder R; Wells DA
    Leuk Res; 2007 Jun; 31(6):727-36. PubMed ID: 17257673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classification and prognostic evaluation of myelodysplastic syndromes.
    Cazzola M; Della Porta MG; Travaglino E; Malcovati L
    Semin Oncol; 2011 Oct; 38(5):627-34. PubMed ID: 21943669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
    Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.